Trainee of the Month – Kanwaldeep Singh

Kanwaldeep is a member of the Berg Lab. His research focuses on the mechanism of action of a promising drug combination of venetoclax and the LSD1 inhibitor bomedemstat for the treatment of acute myeloid leukemia (AML). His passion for cancer research is fueled by the inherent heterogeneity of cancer, stemming from diverse origins, genetic mutations, and intricate tumor microenvironment interactions. In his spare time, he loves spending time with his son as well as on the cricket pitch.

1.  What is your current research focus?

I am studying the mechanism of action of a promising drug combination of venetoclax and the LSD1 inhibitor bomedemstat for the treatment of acute myeloid leukemia (AML). We have discovered that inhibiting LSD1 with bomedemstat induces metabolic changes in AML cells, enhancing their sensitivity towards venetoclax treatment.

2.  What made you interested in pursuing cancer research?

The inherent heterogeneity of cancer, stemming from diverse origins, genetic mutations, and intricate tumor microenvironment interactions, fuels my passion for cancer research. Understanding the complexity of this disease is essential for personalized medicine. Research in the field of cancer offers hope for patients, and every discovery, no matter how small, brings us closer to better treatments, improved survival rates, and, ultimately, a world without cancer.

3.  What are your interests outside the CDCR and the lab?

Outside the lab, I cherish spending quality time with my son. I also enjoy helping my wife with baking and decorating cakes. Beyond family time, I enjoy watching movies and love playing cricket.